Continuous glucose monitors are in vogue. But do you really need to track your blood sugar?
Continuous glucose monitors, small patches that provide 24-hour insight into concentrations of sugar in the blood, could be a tool for Americans to 'take control over their own health,' Health Secretary Robert F. Kennedy Jr. recently told federal lawmakers.
'They can take responsibility,' Kennedy said. 'They can begin to make good judgments about their diet, about their physical activity, about the way they live their lives.'
The devices have lifesaving benefits for people with diabetes, the disease caused when blood sugar remains high because their bodies don't make enough insulin or become resistant to it. The condition, which affects more than 38 million people in the U.S., raises the risk of serious health problems such as heart and kidney disease and vision loss.
But the devices have surged in popularity among people without diabetes. Sales have been driven by high-profile marketers such as Casey Means, the nominee for U.S. surgeon general.
There's scant evidence the monitors are useful for people with normal blood sugar levels, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center.
Healthy bodies can effectively regulate glucose after meals and provide the energy they need to function. Glucose monitors may lead people to misinterpret normal swings in blood sugar that happen after eating or activity. In addition, the devices can be 'notoriously inaccurate,' providing misleading readings, she said.
'The problem with wearing these is that you can just be zooming in on and creating pathology when it's not there,' Dushay said.
Here's what you need to know about the devices:
Here's what a continuous glucose monitor does
The device is a small patch, about the size of two stacked quarters, usually placed on the upper arm or stomach. It uses a needle to painlessly pierce the skin for a tiny sensor.
The sensor measures the glucose in fluid under the skin, delivering a signal every few minutes to a phone app or a handheld display. The apps typically record blood sugar levels and help people track the foods they eat and how they impact those levels.
When healthy people eat a meal that contains carbohydrates, their blood sugar rises, peaks and falls in response to the food.
A healthy fasting blood glucose level for a person without diabetes is roughly 70 milligrams per deciliter to 99 milligrams per deciliter. A range from 100 to 126 milligrams per deciliter indicates prediabetes and above 126 milligrams per deciliter indicates diabetes, according to the American Diabetes Association.
In adults without diabetes, blood sugar levels can climb to 140 milligrams per deciliter or more within an hour of a meal, before falling back to baseline levels within two or three hours, according to the association. It's a sign the body is processing sugar normally.
Continuous glucose monitors have been available since the late 1990s
For decades, these devices were available only for people with diabetes. The monitors revolutionized care by allowing more precise adjustment of insulin used to treat diabetes and giving people the ability to modify meals and activity more accurately.
Last year, the U.S. Food and Drug Administration approved the first over-the-counter monitors. Since then, many companies have emerged to market them, claiming to provide intensive, individualized health monitoring. Cost is generally about $100 a month.
They've really caught on with consumers curious about how food and activity affect their blood sugar levels. For instance, Noom, the weight-loss and fitness app, launched a blood glucose feature last year that has proven extremely popular, said Alexander Fabry, a company executive.
'Of the people who are using a CGM, the vast majority of them don't have a diabetes diagnosis,' he said.
Who can use the monitors?
The devices have been lifesaving for people with diabetes. And they can be helpful for people with risk factors for the disease, including obesity, prediabetes, a history of gestational diabetes or a family history of the condition.
The devices can allow users to see how specific food and activity choices affect their blood sugar in near real-time, said Dr. Alaina Vidmar, a pediatric obesity specialist at Children's Hospital Los Angeles.
'After a large meal, you may watch your blood sugar go up and sort of learn something about yourself,' Vidmar said. 'For example, I drink a sugar-sweetened soda and my blood sugar goes up really high, really fast. And maybe I don't feel as good, right?'
What are the cautions?
People without risk factors for diabetes may turn to the monitors just because they're curious, said Dr. David Kessler. A former FDA commissioner, Kessler doesn't have diabetes, but he wore a monitor for a couple months during research for his recent book, 'Diet, Drugs and Dopamine.'
'I think it's a very interesting tool to experiment with if you're so inclined,' Kessler said.
But, he noted, the devices can't be used to diagnose or treat disease. Even experts don't agree on how to interpret or provide health advice for people without diabetes based on blood sugar data.
'No one knows what's optimal in the nondiabetic state,' he said.
Before using a monitor, Dushay asks patients to consider their motives.
'What do you think you're going to get from the data?' she said. 'What is to be gained from wearing that monitor?'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement
-- Heinley to focus on strategic growth, and joins the leadership team of Sam Brown, a Blue Matter Company -- WAYNE, Pa. & NEW YORK, August 04, 2025--(BUSINESS WIRE)--Sam Brown Healthcare Communications, a Blue Matter Company, is proud to announce the appointment of Michael Heinley to the new position of Managing Director, Client Development and Engagement, reporting to Founder and President Laura Liotta. With deep in-house and agency PR experience in the life sciences industry, Heinley is a highly seasoned counselor with a proven record of strategic communications impact across leading global organizations. These include senior leadership roles at Johnson & Johnson, Merck & Co., Inc., and WebMD. Most recently, as Senior Partner in the Finn Partners Global Health Practice, he led client development and engagement for pharmaceutical, biotech, health tech, med tech, health systems, professional societies, and advocacy organizations. "In today's fast-moving and complex healthcare environment, Michael has a distinct perspective leading corporate, scientific, marketing, and brand storytelling campaigns that build trust, strengthen reputation, and deliver meaningful business results," said Laura Liotta, Founder and President of Sam Brown. "In this new role at Sam Brown, Michael will be instrumental in delivering innovative solutions, expanding our services and markets globally, and enabling our integrated teams to help clients adapt and lead in an evolving landscape." Throughout his career, Heinley oversaw multiple global pharmaceutical product launches, R&D communications, employee engagement, financial/IR communications, reputation and issues management, CEO and C-suite counsel, and executive thought leadership. Heinley was named among the industry's most influential leaders and Mentor of the Year by PM360. He currently serves on the Board of Directors for Donate Life New York State, a statewide nonprofit dedicated to increasing organ and tissue donation. "I'm thrilled to join the talented team at Sam Brown to help drive the agency's continued growth and success," said Heinley. "Under Laura's leadership, I've deeply admired the 'Sam Brownie' culture—recognized for building and sustaining enduring client partnerships through strategic expertise, hands-on senior counsel, and integrated creative excellence." About Sam Brown Healthcare Communications For 26 years, Sam Brown has been a leading healthcare-focused corporate, clinical, and commercial communications agency for the life sciences industry. Sam Brown provides broad strategic communications services to a wide range of biotechnology, biopharmaceutical, and venture capital companies whose cutting-edge science and innovation impact human health. For more information, visit About Blue Matter Blue Matter is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies from around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels. It has broad therapeutic expertise with a focus on complex markets such as oncology, CNS, and rare diseases. For more information, visit View source version on Contacts Media Contact: Christy CurranSam Brown Inc.615.414.8668christycurran@ Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
UnitedHealth Group names new CFO
UnitedHealth Group has appointed Wayne DeVeydt as its new chief financial officer (CFO), succeeding John Rex. Rex, having served as CFO since 2016, will transition to a strategic advisory role to the CEO. UnitedHealth chairman and CEO Stephen Hemsley said: 'John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission. I look forward to his continued insights as UnitedHealth Group moves forward. 'Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to healthcare that is a perfect fit for UnitedHealth Group.' With a background in healthcare finance and operations, DeVeydt's experience includes his recent tenure as a managing director and operating partner at Bain Capital. Prior to Bain, he served as chairman and CEO of Surgery Partners, where he oversaw the company's operational scope between 2018 and 2020. He held the position of CFO at Anthem (now Elevance) from 2007 to 2016, having joined the company in 2005. Prior to his time at Anthem, he was a partner at PricewaterhouseCoopers, focusing on healthcare. DeVeydt stated: 'There is no organisation besides UnitedHealth Group that presents the kinds of opportunities to make a difference in healthcare, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team. 'I have been fortunate to know John Rex for over two decades and am honoured to follow a leader of his calibre.' In May, Hemsley was named CEO of UnitedHealth following the departure of Andrew Witty due to personal reasons. "UnitedHealth Group names new CFO " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Associated Press
9 minutes ago
- Associated Press
Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement
WAYNE, Pa. & NEW YORK--(BUSINESS WIRE)--Aug 4, 2025-- Sam Brown Healthcare Communications, a Blue Matter Company, is proud to announce the appointment of Michael Heinley to the new position of Managing Director, Client Development and Engagement, reporting to Founder and President Laura Liotta. This press release features multimedia. View the full release here: Michael Heinley With deep in-house and agency PR experience in the life sciences industry, Heinley is a highly seasoned counselor with a proven record of strategic communications impact across leading global organizations. These include senior leadership roles at Johnson & Johnson, Merck & Co., Inc., and WebMD. Most recently, as Senior Partner in the Finn Partners Global Health Practice, he led client development and engagement for pharmaceutical, biotech, health tech, med tech, health systems, professional societies, and advocacy organizations. 'In today's fast-moving and complex healthcare environment, Michael has a distinct perspective leading corporate, scientific, marketing, and brand storytelling campaigns that build trust, strengthen reputation, and deliver meaningful business results,' said Laura Liotta, Founder and President of Sam Brown. 'In this new role at Sam Brown, Michael will be instrumental in delivering innovative solutions, expanding our services and markets globally, and enabling our integrated teams to help clients adapt and lead in an evolving landscape.' Throughout his career, Heinley oversaw multiple global pharmaceutical product launches, R&D communications, employee engagement, financial/IR communications, reputation and issues management, CEO and C-suite counsel, and executive thought leadership. Heinley was named among the industry's most influential leaders and Mentor of the Year by PM360. He currently serves on the Board of Directors for Donate Life New York State, a statewide nonprofit dedicated to increasing organ and tissue donation. 'I'm thrilled to join the talented team at Sam Brown to help drive the agency's continued growth and success,' said Heinley. 'Under Laura's leadership, I've deeply admired the 'Sam Brownie' culture—recognized for building and sustaining enduring client partnerships through strategic expertise, hands-on senior counsel, and integrated creative excellence.' About Sam Brown Healthcare Communications For 26 years, Sam Brown has been a leading healthcare-focused corporate, clinical, and commercial communications agency for the life sciences industry. Sam Brown provides broad strategic communications services to a wide range of biotechnology, biopharmaceutical, and venture capital companies whose cutting-edge science and innovation impact human health. For more information, visit About Blue Matter Blue Matter is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies from around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels. It has broad therapeutic expertise with a focus on complex markets such as oncology, CNS, and rare diseases. For more information, visit View source version on CONTACT: Media Contact: Christy Curran Sam Brown Inc. 615.414.8668 [email protected] KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA NEW YORK INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL PUBLIC RELATIONS/INVESTOR RELATIONS GENERAL HEALTH HEALTH CONSULTING COMMUNICATIONS PROFESSIONAL SERVICES SOURCE: Sam Brown Healthcare Communications Copyright Business Wire 2025. PUB: 08/04/2025 07:30 AM/DISC: 08/04/2025 07:30 AM